Prelude Therapeutics Incorporated
PRLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $7 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $118 | $103 | $93 | $87 |
| G&A Expenses | $29 | $29 | $31 | $27 |
| SG&A Expenses | $29 | $29 | $31 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $147 | $132 | $124 | $114 |
| Operating Income | -$140 | -$132 | -$124 | -$114 |
| % Margin | -1,995.9% | – | – | – |
| Other Income/Exp. Net | $13 | $10 | $8 | $2 |
| Pre-Tax Income | -$127 | -$122 | -$115 | -$112 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$127 | -$122 | -$115 | -$112 |
| % Margin | -1,816.8% | – | – | – |
| EPS | -1.68 | -2.02 | -2.27 | -2.33 |
| % Growth | 16.8% | 11% | 2.6% | – |
| EPS Diluted | -1.68 | -2.02 | -2.27 | -2.33 |
| Weighted Avg Shares Out | 76 | 60 | 47 | 48 |
| Weighted Avg Shares Out Dil | 76 | 60 | 47 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $1 |
| EBITDA | -$138 | -$131 | -$122 | -$113 |
| % Margin | -1,970.6% | – | – | – |